|
- 积分
- 244
- 威望
- 244
- 包包
- 616
|
本帖最后由 细胞海洋 于 2016-1-23 09:51 编辑
. z* `0 u2 M' t. y m$ Z- N, p9 W( e6 F0 @
目录; j" m; F; d( x3 s: |# I- f( y% N* M
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4' U' J4 p4 k: |
抗癌领域新突破 .................................................................................................................. 4/ g1 C/ `5 R3 M- N& ~ D
600 亿美元市场空间 ............................................................................................................ 4
- E/ t+ Q8 A7 k5 U& S* m& n免疫检查点的突破——PD-1 ....................................................................................................... 5
- m8 M9 N0 h; c& n" H" tPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5: a8 q7 q$ }* s! ~0 d
PD-1 重磅产品频出 ............................................................................................................. 5/ ]# [( [. c0 s3 Q
在研PD-1 单抗全面开花 ....................................................................................................... 6+ D* d# e u7 _5 v* u' x; k
PD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7' p( R N$ X& p5 @/ ^/ v
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
& |" ?0 s# D }8 c# a2 E f8 U, IPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 99 B- j0 N" B2 W" i, ]. }! [! x# {
PD-1 市场前景广阔 ........................................................................................................... 10
$ ^; u; L, F7 q, r2 O3 G免疫治疗热门靶点——PD-L1 ................................................................................................... 19
0 U: x/ g/ G8 l# r) a N& oPD-L1 单抗免疫疗法原理 .................................................................................................... 19
* V1 h# C5 _1 {PD-L1 单抗在研情况 .......................................................................................................... 19% C+ w3 V4 q8 d" v/ _
PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19. Y4 `% n9 m$ {% N/ Y- U s
PD-L1 未来市场 ............................................................................................................... 20; e' j7 N- y9 [7 C
免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
$ o4 @, w0 Q3 O: f0 n4 T, `CTLA-4 单抗免疫疗法原理 ................................................................................................... 211 c( }3 l* X) }9 l
CTLA-4 单抗已上市产品 ..................................................................................................... 21
: }9 _/ r$ h$ D! V7 b( bCTLA-4 在研产品.............................................................................................................. 22/ D4 r0 \7 u( l0 ^
CTLA-4 的未来，联合用药是出路 .......................................................................................... 23
+ w/ ?2 _! \0 o) m相关公司简介 ........................................................................................................................ 245 l& f( t1 b0 G
君实生物 ........................................................................................................................ 24, z3 h/ U8 |. j+ `
恒瑞医药（确信买入评级） .................................................................................................. 25 B7 I) W2 b; g' U. y
百时美施贵宝（BMS） ....................................................................................................... 26% g1 |( R( j/ F4 _+ l, }
默克（Merck） ................................................................................................................ 27
, l, u$ t& G" ~- ^1 O8 b0 O( a! C0 \/ F8 y" R7 C9 t
- P$ U* t' [# _7 M& `[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2016-1-23 09:08
发表于 2016-1-23 19:55
